Wedbush bullish on Zura Bio, initiates with an Outperform

As previously reported, Wedbush initiated coverage of Zura Bio (ZURA) with an Outperform rating and $15 price target The firm sees a favorable near- and long-term setup with shares likely to appreciate through 2026 as the market anticipates the first readout for an IL-17 combination candidate in hidradenitis suppurativa, followed by de-risked clinical readouts in the next 12-18 months.